Showing posts with label national vaccination program. Show all posts
Showing posts with label national vaccination program. Show all posts

Monday 2 August 2021

About those up to 40,000 Pfizer COVID-19 vaccine doses withdrawn from rural & regional New South Wales at the end of July 2021.....



In 2021 the New South Wales Higher School Certificate written exams for Year 12 students commence on 19 October and conclude on 12 November.


In Greater Sydney there are est. 52,400 students enrolled in Year 12 and it seems that the NSW Berejiklian Government has been unable to persuade Australian Prime Minister & Liberal MP for Cook Scott Morrison to release enough Pfizer COVID-19 vaccine to protect an est. 24,153 of these students living in Western and South Western Sydney during the current highly infectious Delta Variant Outbreak.  Despite the fact that children and adolescents are over represented in the current infection growth within the state and there is as yet no end date in sight for this viral outbreak.


ABC News, 28 July 2021






On 28 July 2021 NSW Health announced that: Up to 40,000 Pfizer doses will be allocated from NSW Health's rural and regional supply of COVID-19 vaccine to help Year 12 students in south west and western Sydney get back to school for face-to-face learning on 16 August.


By 31 July people in regional NSW were beginning to report receiving cancellation notices for scheduled appointments for first and second doses of the Pfizer vaccine, as well as at least one vaccination hub being stripped of Pfizer completely.



Twitter
, retrieved 1 August 2021


One has to wonder about the logistics of the Premier and Health Minister’s plan to first dose vaccinate those approx. 24,153 high school students - who along with their peers are currently studying from home during the Greater Sydney lockdown – over a short window of 18 days.


Given the ever rising infection numbers, people living in rural and regional New South Wales are openly wondering if any thought has been given to the impact on their communities once the Delta Variant firmly establishes itself outside of Greater Sydney.


Friday 25 June 2021

The Pfizer COVID-19 vaccine is being rolled out in northern New South Wales for people aged from 40 to 59 years

 

Port Macquarie News, 23 June 2021, article excerpt:


The Ballina Commonwealth Vaccination Clinic began administering the Pfizer COVID-19 vaccine this week and will be able to start accepting people aged 40 to 59.


Planning is underway to increase the number of Commonwealth vaccination clinics offering the Pfizer vaccine.


The other six Commonwealth vaccination clinics in the region are at Wauchope, Kempsey, Murwillumbah, Casino, Yamba and Nambucca Heads.


Additionally, 20 local general practices are due to begin administering the Pfizer vaccine from July 5, with a further 10 starting on July 12.


More practices are expected to come on board from July 19.


There are more people in line for the Pfizer vaccine after the federal government announced that Pfizer is the preferred vaccine for people aged 59 and under, based on updated advice from the expert vaccine body.


BACKGROUND


Australian Technical Advisory Group, statement excerpt,

17 June 2021:



A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) on the AstraZeneca COVID-19 vaccine in response to new vaccine safety concerns.



Summary


The Australian Technical Advisory Group on Immunisation (ATAGI) recommends the COVID-19 Pfizer vaccine (Comirnaty) as the preferred vaccine for those aged 16 to under 60 years. This updates the previous preferential recommendation for Comirnaty over COVID-19 Vaccine AstraZeneca in those aged 16 to under 50 years. The recommendation is revised due to a higher risk and observed severity of thrombosis and thrombocytopenia syndrome (TTS) related to the use of AstraZeneca COVID-19 vaccine observed in Australia in the 50-59 year old age group than reported internationally and initially estimated in Australia.


Australian GovernmentTherapeutic Goods Administration (TGA)COVID-19 vaccine weekly safety report - 17-06-2021, snapshot:




Five of the twelve cases of confirmed or probable adverse reactions resulting in Thrombosis with thrombocytopenia syndrome (TTS) after being administered the AstraZeneca COVID-19 vaccine recorded between 11 and 17 June 2021 were in people aged between 65 and 80 years of age.


Australian GovernmentTherapeutic Goods Administration (TGA)COVID-19 vaccine weekly safety report - 24-06-2021, snapshot:



Two of the five cases of confirmed or probable adverse reactions resulting in Thrombosis with thrombocytopenia syndrome
(TTS) after being administered the AstraZeneca COVID-19 vaccine recorded between 18 and 24 June 2021 were in people aged between 60 and 95 years of age.


As of 24 June 2021 there have been a total of 64 cases of confirmed & probable TTS reported from approximately 4.2 million AstraZeneca vaccine doses and, as of 20 June 2021 there have been a total of 38 reports of the immune disorder Guillain-Barre Syndrome (GBS) following approximately 4.2 million doses of the AstraZeneca vaccine. GBS causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking. In many cases it resolves within months but can sometimes take up to two years.


Australian Government Dept. Of Health, "Information for health care providers to help consumers make informed decisions", 18 June 2021:
 

TTS involves blood clotting with low platelet count. Current data indicates that TTS occurs in around 2 out of every 100,000 people who receive the first dose of COVID-19 Vaccine AstraZeneca. TTS appears to be far more rare following second doses, with data from the United Kingdom indicating a rate of 1.5 per million second doses. The severity of illness due to TTS ranges from fatal cases and those with significant morbidity, to relatively milder cases. TTS appears to be more severe in younger people. In Australia, the overall case fatality rate is 3%. Of the TTS cases that have been classified by the Therapeutic Goods Administration as confirmed or probable, over half have been discharged from hospital. Around a quarter of the Australian cases so far have been more serious and have required treatment in intensive care, and tragically two people have died.




Friday 18 June 2021

A statement from some of the health experts who first told Australians that the AstraZeneca COVID-19 vaccine (ChAdOx1-S) was perfectly safe to administer to all adults, then 'modified' that assurance to safe for all adults 50 years of age & older and now announces that it is only safe for those adults 60 years of age and older

 

Australian Technical Advisory Group, statement excerpts,,

17 June 2021:


A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) on the AstraZeneca COVID-19 vaccine in response to new vaccine safety concerns.


Summary


The Australian Technical Advisory Group on Immunisation (ATAGI) recommends the COVID-19 Pfizer vaccine (Comirnaty) as the preferred vaccine for those aged 16 to under 60 years. This updates the previous preferential recommendation for Comirnaty over COVID-19 Vaccine AstraZeneca in those aged 16 to under 50 years. The recommendation is revised due to a higher risk and observed severity of thrombosis and thrombocytopenia syndrome (TTS) related to the use of AstraZeneca COVID-19 vaccine observed in Australia in the 50-59 year old age group than reported internationally and initially estimated in Australia.


For those aged 60 years and above, the individual benefits of receiving a COVID-19 vaccine are greater than in younger people. The risks of severe outcomes with COVID-19 increase with age and are particularly high in older unvaccinated individuals. The benefit of vaccination in preventing COVID-19 with COVID-19 Vaccine AstraZeneca outweighs the risk of TTS in this age group and underpins its ongoing use in this age group.


People of any age without contraindications who have had their first dose of COVID-19 Vaccine AstraZeneca without any serious adverse events should receive a second dose of the same vaccine. This is supported by data indicating a substantially lower rate of TTS following a second COVID-19 Vaccine AstraZeneca dose in the United Kingdom (UK).


Background


The Australian COVID-19 vaccination program has the overarching goal of protecting all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2.


On 8 April 2021, ATAGI recommended that Comirnaty was the preferred vaccine for people under the age of 50 years due to local and international reports of thrombosis and thrombocytopenia syndrome (TTS) following COVID-19 Vaccine AstraZeneca.


Based on available international data at that time, the estimated risk of TTS was 4-6 per million cases following a first dose of COVID-19 Vaccine AstraZeneca. Given the ongoing risk of COVID-19 outbreaks, low vaccine coverage, and increasing rate of severe COVID-19 outcomes in older individuals, it was considered that the benefits of COVID-19 Vaccine AstraZeneca outweighed the risk in those over 50 years. As such, no preferential recommendation for either vaccine was made in this age group. This advice was reinforced on 23 April 2021 and has been reviewed weekly by ATAGI since then.


Principles underpinning the revised recommendations


In making the decision to revise the previous recommendation, ATAGI has considered several factors that have been monitored closely, including:


  • The potential risk of severe illness and death from COVID-19 over the coming months

  • Minimising harms to people due to adverse events following immunisation

  • Australian data on the age-specific risks and severity of TTS following COVID-19 Vaccine AstraZeneca

  • The expected vaccine supply over the months ahead

  • The impacts of any change in recommendation on the COVID-19 vaccine program……


The risks of TTS after COVID-19 Vaccine AstraZeneca


From early April to 16 June 2021, 60 cases of confirmed or probable TTS have been reported in Australia. This includes an additional seven cases reported in the past week in people between 50-59 years, increasing the rate in this age group from 1.9 to 2.7 per 100,000 AstraZeneca vaccine doses. The revised estimates of risk associated with first doses of COVID-19 Vaccine AstraZeneca are listed in the table below.



TTS is a serious condition in a proportion of individuals who develop it. The overall case fatality rate in Australia (3%; 2 deaths among 60 cases) is lower than has been reported internationally. This is likely to reflect increased detection due to heightened awareness, as well as early diagnosis and treatment. A spectrum of severity of illness has been reported in Australia, from fatal cases and those with significant morbidity, to relatively milder cases. TTS appears to be more severe in younger people.



There are different ways in which the severity of TTS can be measured. The US Centers for Disease Control and Prevention (CDC) defines “tier 1” cases as clots involving unusual sites, such as the veins of the brain (cerebral venous sinus thrombosis) or abdomen (splanchnic thrombosis); these are generally more severe and may potentially lead to long term health complications. In those under 60 years, 52% of TTS episodes are occurring in tier 1 sites compared with 28% in those 60 years and older. Other markers of severity include the requirement for intensive care (33% of TTS in those under 60 years; 15% of TTS cases in those 60 years and older), and fatal cases (both occurring in those < 60 years)……


Second dose recommendations for COVID-19 Vaccine AstraZeneca

ATAGI supports completion of a two-dose schedule with COVID-19 Vaccine AstraZeneca, based on current evidence. The risk of TTS following a second dose of COVID-19 Vaccine AstraZeneca is much lower than the risk following a first dose. The UK has reported 23 TTS cases in 15.7 million people after receiving a second dose, an estimated rate of 1.5 per million second doses (compared to a reported risk of 14.2 per million first doses in the UK).


People of any age without contraindications who have had their first dose of COVID-19 Vaccine AstraZeneca without any serious adverse events should receive the second dose.


Recommendations


  • ATAGI advises that Comirnaty is preferred over COVID-19 Vaccine AstraZeneca from the age of 16 to under 60 years. This is based on recent data regarding TTS cases in Australia and a reassessment of current age-specific risks and benefits of vaccination.

  • ATAGI considers the benefit of vaccination in preventing COVID-19 with COVID-19 Vaccine AstraZeneca outweighs the risk of TTS in people aged 60 and above. For this age group, the benefits of receiving a COVID-19 vaccine are greater than in younger people. The risks of severe outcomes with COVID-19 increase with age and are particularly high in older unvaccinated individuals.

  • COVID-19 Vaccine AstraZeneca can be used in adults aged under 60 years for whom Comirnaty is not available, the benefits are likely to outweigh the risks for that individual and the person has made an informed decision based on an understanding of the risks and benefits.

  • People of any age without contraindications who have had their first dose of COVID-19 Vaccine AstraZeneca without any serious adverse events should receive the second dose.

  • ATAGI reinforces the importance of providing clear communications to people who have received or are considering COVID-19 Vaccine AstraZeneca, and notes guidance documents for consumers, for primary care and for hospitals are being continually revised to accommodate this new recommendation.....


Read full statement here


It is noted that of the 60 cases (29 men and 31 women) to date with confirmed and probable adverse reactions to the AstraZeneca vaccine resulting in thrombosis with thrombocytopenia syndrome (TTS):


  • the majority of people diagnosed with TTS are over 50 years of age - only 6 people aged under 50 years had a TTS diagnosis; 


  • 23 of the 60 individuals listed were diagnosed with the most severe forms of TTS (CDS classification Tier 1);


  • 6 of those with the most severe forms of TTS were aged in 60-65 age group through to the 80+ age group; 


  • Across all age groups, from under 30 years upwards, it was the 70-79 age grouping which had the highest number of TTS diagnoses at 19 cases (comprising Tier 1, Tier 2 & unclassified), with an est. risk rate of 1.8 TTS cases per 100,000 AstraZeneca first doses; and


  • There were 12 new confirmed and probable cases of TTS attributed to the AstraZeneca vaccine in the week of 11-17 June 2021 in Australia, with 5 of those cases being in individuals over 60 years of age and 7 cases in individuals below 60 years of age.


Wednesday 9 June 2021

Less talk about a 2021 federal general election since the impact of Morrison's vaccine procurement & rollout blunders began to bite

 

The hoped for strong surge in support for the Coalition parties is not being realised, while Australian Prime Minister Scott Morrison's personal support has been falling since his late April high this year.

An October 2021 federal general election is becoming less of a certainty and News Corp media is reporting that Morrison is telling colleagues that the election will not be held until 2022, with 21 May being put forward as a possible date by former senior Abbott advisor and current Liberal Party campaign director Andrew Hirst.


Newspoll 4-5 June 2021



















An online survey of 1,516 respondents conducted by YouGov between Wednesday 2 and Saturday 5 June. The previous survey was conducted on 13-15 May 2021.


Primary vote:

Coalition 41% (unchanged)

Labor 36% (unchanged)

The Greens 11% (-1)

One Nation 3% (+1)

Others 9%

* 7% uncommitted excluded


Two party preferred vote:

Coalition 50% (+1)

Labor 50% (-1)

* preference flows based on recent federal and state elections.


Performance Rating:

Morrison - Satisfied 54% (-4) Dissatisfied 43% (+5) Uncommitted 3% (-1)

Albanese - Satisfied 38% (-1) Dissatisfied 47% (+1) Uncommitted 15% (unchanged)


Better Prime Minister:

Morrison 53% (-2)

Albanese 32% (+2)

Uncommitted 15% (unchanged) 



Essential Report 8 June 2021 


A weekly online survey conducted over 5 days with 1,000+ respondents on average.


  • 40% of Australians say they now view Scott Morrison’s federal government less favourably than they did a year ago. A quarter (25%) say they view this more favourably than they did a year ago, and 35% say their views on the federal government have not changed.


  • Compared to other Australians, Victorians are more likely to say they view Scott Morrison’s federal government less favourably than they did a year ago. Just under half (48%) of Victorians say this, followed by 45% of Western Australians, 39% of Queenslanders, 37% of South Australians and 34% of those in NSW.


  • Since peaking at 70% in March, positive rating of the federal government’s handling of Covid-19 has dropped off; falling to 53% this month which is the lowest rating seen since March last year when this question was first asked.


  • Positive rating of the federal government’s handling of Covid-19 has decreased in all states since last month, however it has fallen the most steeply in Victoria where it is now 42% (down 15 percentage points from 57% in May); disapproval of the federal government’s handling of Covid-19 has increased to 36% (from 22% last month) among Victorians.


  • Just under half (48%) of participants believe that Scott Morrison would make a better PM than Anthony Albanese (50% last month).



Monday 31 May 2021

COVID-19 Pandemic 2020-21: Morrison Government still not listening to the experts

 

The New Daily, 30 May 2021:


The numbers used by the federal government to defend the effectiveness of hotel quarantine are wrong, one of Australia’s leading epidemiologists has said.


The criticism comes amid growing calls for every state and territory to have a purpose-built facility, as new analysis shows purpose-built quarantine costs a fraction of the economic cost of lockdowns.


Last month Prime Minister Scott Morrison sought to downplay concerns Australia would keep yoyo-ing in and out of lockdown until issues in hotel quarantine were fixed.


A system that is achieving 99.99 per cent effectiveness is a very strong system and is serving Australia very well,” Mr Morrison said.


If I was to tell you [last year] that would achieve a 99.99 per cent success rate, you wouldn’t have believed me. No one in this country would have believed me. I would have found that hard to believe.”


But Mary-Louise McLaws, an infectious diseases expert at the University of New South Wales and member of the World Health Organisation’s COVID-19 response team, said the PM’s figure was wrong.


I have no idea where it’s been plucked out of,” Professor McLaws told The New Daily.


Around 70 per cent of total cases since Australia closed its borders on March 20 last year have directly and indirectly come from quarantine breaches and exemptions, she said.


Approximately 21,000 people have been infected due to those breaches and exemption.


Professor McLaws said the Australian government needed to “turn 180 degrees and rethink” the quarantine system, to save itself money and protect its citizens.


Lockdown costs $1billion a week for NSW or Victoria,” she said.


Pointing to the Northern Territory’s Howard Springs quarantine facility, which has not leaked a single case into the community, she said states need their own purpose-built facilities, not hotels.


Victoria has estimated they could make a purpose-built for $700 million. That’s less than the cost of a one-week lockdown,” Professor McLaws said.


In WA, they could make a 1000-bed facility that would cost between $80 million and $200 million – that’s still a fraction.


So when people say this is too expensive, I say try $1 billion a week.”…..


News.com.au, 29 May 2021:


A Melbourne doctor has delivered a spray at the PM on national television as frustration boils over about the Government’s biggest headache.


Frontline emergency physician Dr Stephen Parnis took aim at Prime Minister Scott Morrison on Friday morning after Victoria was thrust into its fourth lockdown since the pandemic began.


He told the ABC that Victorians are “getting tired of hearing excuses” about things that “should have happened earlier this year, at least”.


He was referring to delays in the Covid-19 vaccine rollout and the Commonwealth’s slow take-up of advice to build a fit-for-purpose quarantine facility that does not involve placing infected people in hotel rooms.


It’s taking too long,” Dr Parnis said. “It should have happened earlier this year, at least. We need to do it right now. [New quarantine facilities] has the same urgency as vaccinating our nursing home populations.


We know that this virus has airborne transmission. We know that the best protocols will still not be foolproof in hotels that are designed for tourists. Each state and territory will have plans for these things. But they are waiting for the checks to come from Canberra and those checks have been delayed,” Dr Parnis said.


That is unacceptable, I think, to the medical profession, and it should be unacceptable to the wider population.”


It is a sentiment shared by Melbourne GP Dr Vyom Sharma. He told news.com.au there is nowhere near enough being done to stop leaks from HQ.


There are no nationally consistent guidelines for infection prevention and control,” he said.

Different states have different standards for Personal Protective Equipment (PPE) — some will use simple surgical masks when near travellers, others will use N95 respirators.


Some states have performed ventilation audits and upgrades. Others either have not, or have not reported this publicly. This inconsistency risks further instances of airborne transmission within quarantine.”


He said staff working in medi-hotels are not being protected.


Any staff within line of sight of a returned traveller should be wearing an N95 mask. That is a no brainer, and an instant fix — source the materials, fit test all staff.


Also, and I can only hope this is the case in all states, make vaccination mandatory for all staff, and do not allow them on site until two weeks after the second dose.”


Dr Sharma said the problem was no going to disappear and that only fit-for-purpose accommodation would prevent more outbreaks.


More leaks are inevitable if things stay the same. Only a fool would bet otherwise.”


The problem with using hotel quarantine to house overseas arrivals from Covid-19 hotspots was raised with the Prime Minister on Thursday after Acting Victorian Premier James Merlino revealed the holdup in building an broadacre facility was at a federal level.


We are waiting on the green light in terms of going ahead,” he said in relation to a proposal to build such a facility at Avalon or Mickleham partly funded by both state and federal governments.


Mr Morrison said he was “highly favourable” of the Victorian plan but did not make a firm commitment.


Melbourne surgeon Dr Eric Levi expressed his frustration at Victoria being forced into another lockdown because quarantine issues had not been sorted.


Let’s learn from this. AGAIN,” he wrote on Twitter.


One person was Covid negative on multiple swabs, spent two weeks in hotel quarantine in Adelaide. Caught Covid from the room next door. Flew back to Melbourne. Tested positive.


Now thousands of primary and secondary contacts. One person in ICU.


More than 150 exposure locations. And a state in lockdown. Again. It’s 16 months into the pandemic. Should we not have learned this last year. Can we fix upstream quarantine problems before it causes downstream catastrophe?


Covid is airborne. Majority of those with Covid have no symptoms. By the time they know they’re positive, they’ve shared the virus with others. We now have vaccines to reduce transmission. New variants are emerging.”


Mr Merlino said expressions of interest had been sent out on Friday for the building of a facility at either Avalon or Mickleham, 30km and 56km from the CBD respectively.


But nothing will happen without the Morrison Government’s approval. It will have the final say.


Both sites could work and that will ultimately, because these are both Commonwealth pieces of land, be the decision of the Commonwealth,” Mr Merlino said.



Thursday 13 May 2021

State of Play Australia 2021: Morrison Government mismanagement of national response to the COVID-19 pandemic continues


On 22 February 2021 what should have been the biggest logistical exercise in Australia’s history got underway – the vaccination of the population against the COVID-19 global pandemic caused by the SARS-CoV-2 virus.


This vaccination program launches us down our path out of the COVID-19 pandemic in 2021. Every Australian will be given the opportunity to receive a COVID-19 vaccine, free of charge that has been proven to be safe and effective by our own medical experts.” [Australian Prime Minister Scott Morrison, media release, 21 February 2021]


Eleven months earlier in an effort to contain the spread of viral infection within Australia, the Morrison Government had finally closed Australia’s borders at 9pm AEDT on Friday, 20 March 2020, with exemptions only for Australian citizens, permanent residents (including NZ permanent residents) and their immediate families, including spouses, legal guardians and dependants, as well as Pacific Islanders transiting to their own countries.


From the very start of the pandemic the Morrison Government had refused to take responsibility for creating/re-establishing a national human quarantine system with dedicated purposed-built quarantine facilities. 


Instead an ad hoc system of leased hotels in capital cities was established, primarily operating as quarantine sites under the control of state governments, in order to fill the unmet need to isolate those who at the time were still coming to Australia as tourists, as well as Australians returning from overseas or those transiting through Australia. This ad hoc system allowed COVID-19 to spread into the community on multiple occasions and state border closures became a feature of domestic pandemic response measures.


Commencing on 3 March 2020 there had been repeated announcements from the Prime Minister concerning the development of a COVID-19 vaccine and his government’s successful efforts up to November 2020 to secure over 134 million vaccine doses for the national vaccination program.


In Morrison’s own words “our strategy puts Australia at the front of the queue” for vaccine supply.


By February 2021 most Australians were anticipating the pledge that the adult population would be fully vaccinated by the end of October 2021.


Then we discovered how comprehensively we had been mislead.


There had never been a well-defined strategy behind efforts to obtain enough vaccine doses to provide the Australian population with protection against COVID-19 infection – just what looked suspiciously like a game of mates.


With the AstraZeneca COVID-19 vaccine becoming flavour of the pandemic with Morrison (there was already a Liberal Party connection with that big pharma corporation and with CSL) and an early offer by Pfizer to supply Australia with its COVID-19 vaccine rejected.


Then as international circumstances changed and demand for vaccines began to exceed big pharma stockpiles, it became much more difficult for Australia to successfully compete with other nations for vaccine doses.


As for the national COVID-19 vaccination program rollout, Morrison's plan avoided using the mass vaccination expertise of state and territory departments of health and put together a pottage of primarily private sector vaccine delivery methods which failed to meet the vaccination target of 4 million people receiving their first vaccine dose in the first four weeks of the rollout.


When one looks at the identified priority groups it is clear that by 8 May 2021 only around 260,000 vaccine doses have been administered across the aged care and disability sectors and many frontline health workers were yet to receive their first vaccine dose.


The wheels really fell off the bus when the AstraZeneca vaccine was shown to produce a life threatening adverse reaction in some people days or weeks after receiving a vaccine dose - thrombosis with thrombocytopenia syndrome (TTS).


After one woman died from TTS Morrison declared that the AstraZeneca vaccine would no longer be given to individuals under 50 years of age and, with not enough Pfizer vaccine on hand to vaccinate the under 50s Morrison declared there was no longer a fixed time table for the national vaccination program rollout and no new target would be set for when the Australian population would be fully vaccinated.


Since that early April 2021 decision to keep vaccinating those 50 years of age and older with the problematic AstraZeneca vaccine, 5 people aged between 51 and 74 years of age have been hospitalised with TTS. Bringing to 11 the number of people diagnosed with TTS after receiving an AstraZeneca vaccine dose - that is 11 TTS adverse events in approximately 1.4 million doses administered - with 5 of those 11 people being 64 years of age and older.


So this is now Australia's reality…… 


The Guardian graph showing Australia's vaccine supply as of March-April 2021:




The Guardian graph showing changing 'aspirational' targets and the 2.7 million doses gap between expected doses administered and actual doses administered by 10 May 2021:
















The end result of what appears to be Prime Minister Scott Morrison's personal pandemic strategy - to offload as many federal responsibilities onto the states and territories in the hope of avoiding political blame if things go awry - is that Australia still has (i) no safe and secure national human quarantine system in place; (ii) an inadequate vaccine supply currently on hand; and, (iii)  only est. 12 per cent of its eligible population having received at least a first vaccine dose; at a time when the global pandemic is escalating in the south-east Asia region and highly infectious COVID-19 variants are spreading globally.


Morrison has created the risk that a wave of COVID-19 community transmitted infections, possibly exacerbated by a virus variant, could take off between now and the end of first quarter of 2022.


In a classic political ploy on Tuesday 11 May he began sending his MPs forth to leak his 'private' concerns that the global pandemic was more threatening now than it was a year ago, that COVID-19  remained a danger to Australia as it is "racing" through countries such as India, Indonesia and Papua New Guinea like nothing we had seen in our lifetimes. He warned his MPs against complacency.


Those allegedly private concerns and, an election campaign inspired Budget 2021-22 (that continues to leave establishing Commonwealth human quarantine stations out of federal budgets) which he revealed later on the same day, are apparently supposed to divert the attention of voters. So that we all fail to notice that it is because of his own mismanagement of the federal government's role in the national response to the global pandemic that Australia's national border will need to remain closed until well into the 2022 calendar year.


Prepare for his office to release more publicity photos of prime ministerial visits to defence force bases, walks down red carpets, chin-jutting poses surrounded by flags or twee pics with wife and children. As well as more keynote speeches to industry & assorted lobby groups, along with upbeat announcements of a better future. All scattered as media releases in order to distract both mainstream journalists and the national electorate from pondering that looming public health risk he created.


BACKGROUND


The Guardian, 22 April 2021:


Australia has received just 70% of the vaccine doses the government expected to have on hand by mid-April, according to a Guardian Australia analysis.


In a presentation published online on 14 March, the government included monthly forecasts for Australia’s expected vaccine supply, accounting for the disruptions to overseas supply that had already occurred leading up to that point.


Based on these forecasts, and figures cited by the health minister, Greg Hunt, for the number of doses received from domestic and international suppliers, there is a shortfall of about 1.8m vaccine doses.


The federal government has previously blamed international shipment delays for the slow rollout, which could take a couple of years to complete at the current pace.


However, comparing the government’s forecast with the number of doses we have actually received shows there has also been a shortfall in domestic production, with the number of locally-produced AstraZeneca vaccine doses lower than the government expected.


CSL, the company producing the AstraZeneca vaccine locally, put out a press release in February suggesting it would be able to produce 2m doses by the end of March.


On 24 March, CSL confirmed the release of 830,000 doses, and on 7 April, Hunt revealed CSL had produced at least 1.3 million doses by that point.


When asked why the 2m doses target had been missed, Hunt went into detail about the production and approval process, but did not directly answer the question.


Hunt did, however, indicate that CSL would be scaling up production, and called the production of 1.3m doses so far an “extraordinary achievement”.


It is not clear whether the March forecasts were too optimistic or if there are other issues involved.


According to people familiar with how vaccines are made, the process for creating such a vaccine involves a series of complex biological procedures and involves ongoing refinement, sometimes over several years, to reach peak levels of production.


Guardian Australia sent detailed questions about the vaccine supply shortfall to the health department, and a spokesperson said Pfizer shipments were expected to increase and CSL would produce more than 50m doses this year.


Australia has entered into four separate agreements for the supply of Covid-19 vaccines, if they are proved to be safe and effective,” the spokesperson said in a statement.


These include agreements with Pfizer, AstraZeneca, Novavax and the Covax facility. Combined, these agreements will ensure access to approximately 170 million doses.


As shipments of Pfizer and AstraZeneca are made available, they will be dispatched across Australia to vaccinate the population. Deliveries from Pfizer are expected regularly and will increase over the coming months. CSL is producing 50 million AstraZeneca vaccine doses over the course of this year.”


A CSL spokesperson was positive about production, saying: “Production of the AstraZeneca Covid-19 vaccine is progressing well at both CSL Behring and Seqirus, and the teams continue work around the clock to meet our commitment to the Australian community.


The process for releasing vaccines involves extensive safety and quality checks and no batch is released until all parties – CSL, the TGA and AstraZeneca – are satisfied that each vaccine meets the required quality standards.


CSL is proud of our unique role in manufacturing this vaccine for Australia.”


The government has also now made figures on vaccine utilisation by states and territories available, with the most recent update on 19 April.


South Australia had the lowest utilisation rates, having administered just 59% of the vaccine doses available.


Tasmania and the Australian Capital Territory both had very high rates, at 97% and 98% respectively.


Guardian Australia analysis had previously found that the smaller states were doing better in their rollout on a per-100 population basis. Tasmania, the Australian Capital Territory and the Northern Territory each have administered more than four doses per 100 population.


With more vaccines on the horizon, Dr Mark Hanly from the University of New South Wales says the groundwork has to be laid now for how to administer them out.


[Federal] and state governments need to be planning now for how they will administer 1,000,000 doses a week,” he says. “We need to plan the logistics of how to administer vaccine at a rate that can match supply once local production is up and running. If suitable vaccination facilities aren’t in place, it is possible that the bottleneck will simply shift from supply to administration.”


South Australia is the latest to announce the creation of mass vaccination hubs to speed up the rollout, something Hanly was calling for in February, even before the rollout faltered.


Mass vaccination sites and GPs have different advantages, so a rollout that draws on the benefits of both delivery modes is likely to help us get to high levels of coverage faster than drawing on either mode alone,” he says. “All of this, of course, is contingent on supply and people’s willingness to come forward to be vaccinated.”